Trillium Therapeutics (TRIL) Given New $4.00 Price Target at HC Wainwright

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) had its price objective lowered by HC Wainwright from $10.00 to $4.00 in a report published on Wednesday, The Fly reports. The firm currently has a buy rating on the biotechnology company’s stock.

TRIL has been the topic of a number of other reports. ValuEngine lowered Trillium Therapeutics from a hold rating to a sell rating in a research report on Tuesday, December 25th. Zacks Investment Research lowered Trillium Therapeutics from a buy rating to a hold rating in a research report on Wednesday, November 21st. Finally, Cowen restated a buy rating on shares of Trillium Therapeutics in a research report on Thursday, December 20th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Trillium Therapeutics presently has an average rating of Hold and a consensus price target of $4.67.

NASDAQ TRIL opened at $0.60 on Wednesday. The company has a market cap of $10.06 million, a P/E ratio of -0.25 and a beta of 2.31. Trillium Therapeutics has a one year low of $0.55 and a one year high of $8.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.33 and a current ratio of 3.56.

A number of institutional investors and hedge funds have recently made changes to their positions in TRIL. Morgan Stanley boosted its position in Trillium Therapeutics by 25.2% in the 3rd quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock valued at $2,068,000 after buying an additional 71,860 shares during the last quarter. Geode Capital Management LLC boosted its position in Trillium Therapeutics by 164.0% in the 4th quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 16,541 shares during the last quarter. Two Sigma Investments LP bought a new position in Trillium Therapeutics in the 4th quarter valued at $35,000. Finally, Jane Street Group LLC bought a new position in Trillium Therapeutics in the 4th quarter valued at $43,000. Hedge funds and other institutional investors own 39.43% of the company’s stock.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

See Also: Dividend Aristocrat Index

The Fly

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.